Details for Patent: 11,207,292
Which drugs does patent 11,207,292 protect, and when does it expire?
Patent 11,207,292 protects EPIDIOLEX and is included in one NDA.
This patent has twenty-one patent family members in fifteen countries.
Summary for Patent: 11,207,292
| Title: | Cannabidiol preparations and its uses |
| Abstract: | Cannabidiol (CBD) is a cannabinoid designated chemically as 2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol. Its empirical formula is C21H30O2 and its molecular weight is 314.46. CBD is a cannabinoid that naturally occurs in the Cannabis sativa L. plant. CBD is a white to pale yellow crystalline solid which is insoluble in water and soluble in organic solvents. The present invention encompasses the surprising recognition that certain CBD preparations which are prepared from a botanical origin are more effective in treating diseases or disorders than preparations of CBD which are synthetic or purified to the extent no other impurities in the form of other cannabinoids are present. Prior CBD compositions have been prepared such that no psychoactive components, e.g., tetrahydrocannabinol (THC), remain in the final CBD preparation. Surprisingly, the absence of such minor impurities reduces the efficacy of CBD treatment. Such CBD preparations are characterized by chemical components and/or funtional properties that distinguish them from prior CBD compositions. One or more components of the preparations described herein provide an unexpectedly synergistic effect when utilized in combination. |
| Inventor(s): | Geoffrey Guy, Volker Knappertz, Benjamin Whalley, Marie WOOLLEY-ROBERTS, James Brodie, Katarzyna Lach-Falcone, Alan Sutton, Royston GRAY, Rohini Rajyalaxmi Rana |
| Assignee: | Jazz Pharmaceuticals Research UK Ltd |
| Application Number: | US17/011,715 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,207,292 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 11,207,292
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jazz Pharms Res | EPIDIOLEX | cannabidiol | SOLUTION;ORAL | 210365-001 | Sep 28, 2018 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME | ⤷ Start Trial | |||
| Jazz Pharms Res | EPIDIOLEX | cannabidiol | SOLUTION;ORAL | 210365-001 | Sep 28, 2018 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX | ⤷ Start Trial | |||
| Jazz Pharms Res | EPIDIOLEX | cannabidiol | SOLUTION;ORAL | 210365-001 | Sep 28, 2018 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 11,207,292
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 1806953 | Apr 27, 2018 |
International Family Members for US Patent 11,207,292
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2019259230 | ⤷ Start Trial | |||
| Brazil | 112020021884 | ⤷ Start Trial | |||
| Canada | 3097665 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
